XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Stock-Based Compensation - Stock Option Activity (Details) - Employee Stock Option - $ / shares
 6 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Shares    
Options outstanding at beginning of the period 6,378,924  
Granted 1,818,160  
Exercised (592,738)  
Canceled (71,123)  
Options outstanding at the end of the period 7,533,223 6,378,924
Options vested and expected to vest at the end of the period 7,364,743  
Options exercisable at the end of the period 3,552,278  
Shares available for grant under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 13, 2024) 2,466,466  
Weighted Average Exercise Price Per Share    
Options outstanding at beginning of the period $ 29.69  
Granted 36.50  
Exercised 12.50  
Canceled 165.60  
Options outstanding at the end of the period 31.41 $ 29.69
Options vested and expected to Vest at the end of the period 31.33  
Options exercisable at the end of the period $ 29.05  
Weighted Average Remaining Contractual Term (In Years)    
Options outstanding at the end of the period 7 years 9 months 18 days 7 years 6 months
Options vested and expected to vest at the end of the period 7 years 9 months 18 days  
Options exercisable at the end of the period 6 years 6 months